Press Releases

Aragen Launches CHOMax™, an Accelerated Platform for DNA to IND-Enabling Clinical Supply in ~10 Months

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

PharmaForceIQ Acquires Aktana to Deliver Unparalleled Cross-Functional Engagement Impact for Pharma

PharmaForceIQ has announced its acquisition of Aktana, aligning its cutting-edge digital orchestration platform with the industry’s premier AI-driven field Next-Best-Action (NBA) platform.

Northwell Health and START Center for Cancer Research unveil world-class early-phase cancer clinical trial center

The first START site in New York launches a new strategic partnership to provide cutting-edge cancer research.

CluePoints Scoops Prestigious 2025 Scrip Award

CluePoints, provider of leading statistical and AI-driven software solutions, has won the ‘Best Contract Research Organization– Specialist Providers’ category at the 2025 Scrip Awards.

eClinical Solutions Unveils AI Agents to Power the Next Era of Clinical Data Automation

Built directly into the elluminate ecosystem, the agents combine governed data with explainable intelligence to accelerate decisions

4D Path Collaborates with AMD and Oracle to Scale Predictive Oncology

4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. Using AMD EPYC™ CPUs on Oracle Cloud Infrastructure (OCI), 4D Path’s QPOR™ platform—a physics-informed, AI-driven, deterministic software engine—can convert routine biopsy images into interpretable biomarkers of tumor and immune response faster and at lower cost.

New York Gastroenterology Associates Taps Proscia for Digital Pathology

New York Gastroenterology Associates, LLP (NYGA), New York City’s leading independent gastroenterology practice, is working with Proscia, a pathology AI company, to advance its standard of excellence

New Scale Announces Availability of new DART linear actuator and stage platform

New Scale Technologies is announcing the availability of the new DART linear actuator and stage platform. The DART line is designed to meet the needs of photonic instruments and life science companies looking for smart motion solutions with longer travel and lower cost for high-volume applications. The DART Smart Linear Actuator builds on New Scale’s proprietary SQUIGGLE® technology, offering a greater range of motion and higher force.

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced that the company’s Q-Plasia OncoReader (QPOR™) platform has successfully predicted treatment response in patients with early-stage triple-negative breast cancer (TNBC) using digitized baseline biopsy images. Analysis conducted within the Translational Breast Cancer Research Consortium (TBCRC) 030 clinical trial represents the first demonstration of a statistical physics and tumor biology-based computational biomarker predicting post-treatment outcomes from pre-treatment tissue alone, without any clinical or molecular inputs.

Proscia Achieves SOC 2 Type II Certification, Strengthening Enterprise Trust

Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale

PrecisionLife & Ovation partner to develop first precision medicine test to inform reimbursement of GLP-1 anti-obesity drugs

Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability.

TeleTracking Launches First AI-Powered Patient Throughput Solution, Decision IQ®

Thermo Fisher Scientific Opens East Coast Collaboration Center at BioLabs for Advanced Therapeutics to Help Accelerate Cell and Gene Therapy Development

New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced therapies from early research to clinical readiness

CluePoints Data and Knowledge Manager Appointed to ACT Editorial Advisory Board

CluePoints, provider of leading statistical and AI-driven software solutions, has announced Sylviane de Viron, its Data and Knowledge Manager, has been appointed to the Applied Clinical Trials (ACT) editorial advisory board.

Abselion Launches His-tagged Protein Quantification Kit and Sensors for Amperia at PEGS Europe 2025

• Ready-to-use solution, developed in collaboration with GenScript, offers rapid and reliable quantification of His-tagged proteins • Broadens Amperia’s applications across recombinant protein research, screening, and development • Abselion to showcase kit alongside Amperia platform at PEGS Europe in Lisbon, Portugal from 11–13 November

Baylor Genetics Launches Pharmacogenomic and Germline Genetic Testing for the U.S. Department of Veterans Affairs

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced it was awarded a multi-year national contract from the United States Department of Veterans Affairs (VA) to deliver pharmacogenomic (PGx) testing and germline genetic testing services, which includes hereditary cancer testing to veterans across the VA healthcare system.

Baylor Genetics Applauds Medi-Cal’s Decision to Cover Whole Genome Sequencing

As of Nov. 1, 2025, Medi-Cal (California’s Medicaid) has begun covering whole genome sequencing (WGS). This landmark coverage expands access to WGS for patients across California.

Ambience Healthcare Launches AI-Powered “Conditions Advisor” to Support Comprehensive Inpatient Documentation and High-Quality Care

EazeBio and UC Santa Cruz Announce Strategic Partnership to Advance Instrument-Free Diagnostic Platform

EazeBio has announced a strategic partnership with the University of California, Santa Cruz to advance and commercialize a groundbreaking instrument-free diagnostic platform.